
Johnson & Johnson (J&J) could announce a deal as early as Monday to acquire Texas-based biotechnology company Ollin Biosciences for up to $3.4 billion, according to a Financial Times report citing people familiar with the matter. Under the proposed terms, J&J would pay $2.2 billion upfront in cash, with an additional $1.2 billion linked to potential milestone payments. However, Reuters said it could not independently verify the report.
Ollin Biosciences raised $330 million in June to advance late-stage clinical studies of its experimental drug OLN324, which is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two major causes of vision loss. The potential acquisition would give J&J access to the company’s experimental treatment and strengthen its presence in the ophthalmology segment.
The reported deal follows a series of acquisitions by J&J as it expands its pharmaceutical pipeline. Earlier this year, the company acquired biotechnology firm Firefly Bio for $1 billion in cash to strengthen its oncology portfolio. In 2025, it also completed the $14.6 billion acquisition of Intra-Cellular Therapies to expand its presence in treatments for neurological disorders. Neither J&J nor Ollin Biosciences immediately responded to Reuters’ requests for comment.
Pic Courtesy: google/ images are subject to copyright









